<DOC>
	<DOCNO>NCT00443053</DOCNO>
	<brief_summary>To evaluate fondaparinux 2.5mg subcutaneously daily 45 day treatment acute ( recent ) superficial thrombophlebitis .</brief_summary>
	<brief_title>Evaluation Of Fondaparinux ( Also Called ARIXTRA ) 2.5 mg Subcutaneously Once Daily For The Treatment Of Superficial Thrombophlebitis ( Also Known As Superficial Vein Thrombosis )</brief_title>
	<detailed_description>Comparison ARIXTRA™ low LImb Superficial Thrombophlebitis placebo ( CALISTO ) . An International , Multicentre , Randomised , Double-blind , Placebo-controlled , Two-parallel Group , Phase III Study Evaluate Efficacy Safety ARIXTRA ( 2.5 mg subcutaneously ) Treatment Patients Acute Symptomatic Isolated Superficial Thrombophlebitis Lower Limbs prevent Thromboembolic Complications</detailed_description>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Thrombophlebitis</mesh_term>
	<mesh_term>Fondaparinux</mesh_term>
	<mesh_term>PENTA</mesh_term>
	<criteria>Inclusion criterion : Acute symptomatic superficial thrombophlebitis lower limb least 5 cm long diagnosed compression ultrasound . Exclusion criterion : Superficial thrombophlebitis within 3 cm saphenofemoral junction , deep vein thrombosis ultrasound exam , deep vein thrombosis pulmonary embolism within last 6 month , treatment cancer last 6 month , anticoagulant medication 48 hour prior inclusion , need oral nonsteroidal antiinflammatory drug study , significant bleeding event past month , major surgery within last 3 month , low platelet count ( 100×109/L ) , kidney disease ( Calculated creatinine clearance &lt; 30 mL/min ) , woman childbearing potential use reliable contraceptive method</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>superficial vein thrombosis</keyword>
	<keyword>superficial thrombophlebitis</keyword>
	<keyword>fondaparinux</keyword>
	<keyword>deep vein thrombosis</keyword>
	<keyword>venous thromboembolism treatment</keyword>
	<keyword>thrombosis</keyword>
</DOC>